<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">34861084</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1439-0507</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>65</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Mycoses</Title>
          <ISOAbbreviation>Mycoses</ISOAbbreviation>
        </Journal>
        <ArticleTitle>In vitro activities of 8 antifungal agents against geophilic dermatophyte isolates.</ArticleTitle>
        <Pagination>
          <StartPage>255</StartPage>
          <EndPage>262</EndPage>
          <MedlinePgn>255-262</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/myc.13408</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Members of the Nannizzia gypsea complex are globally the most common geophilic dermatophytes which cause infection in animals and human. Although the susceptibility patterns of anthropophilic or zoophilic dermatophyte species to antifungal agents are well documented, the effectiveness of such drugs against geophilic species have rarely been explored.</AbstractText>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study was aimed to evaluate the in vitro antifungal activity of common and new antifungals against a set of environmental and clinical geophilic dermatophyte isolates.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">108 soil and clinical geophilic isolates from two genera Nannizzia (N. fulva n = 59; N. gypsea n = 43) and Arthroderma (A. quadrifidum n = 4; A. gertleri n = 1; A. tuberculatum n = 1) were included in the study. The in vitro antifungal susceptibility patterns of eight common and new antifungals against the isolates were determined according to broth microdilution method and by CLSI M38-A3 (3rd edition) protocol.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">MIC values across all isolates from five species ranged as: luliconazole: 0.0002-0.002 µg/ml, terbinafine: 0.008-0.125 µg/ml, efinaconazole: 0.008-0.125 µg/ml, ciclopirox olamine: 0.03-0.5 µg/ml, itraconazole: 0.125-1 µg/ml, amorolfine hydrochloride: 0.125-4 µg/ml, griseofulvin: 0.25-2 µg/ml and tavaborole: 1-8 µg/ml, respectively.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Luliconazole, terbinafine and efinaconazole exhibited the highest in vitro efficacy, regardless of the dermatophyte species. Further surveillance studies are recommended to confirm the implication of such in vitro data for the clinical recovery rate of dermatophytosis with geophilic species following antifungal therapy.</AbstractText>
          <CopyrightInformation>© 2021 Wiley-VCH GmbH.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shamsizadeh</LastName>
            <ForeName>Forough</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zarei Mahmoudabadi</LastName>
            <ForeName>Ali</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-5347-2082</Identifier>
            <AffiliationInfo>
              <Affiliation>Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shariat Nabavi</LastName>
            <ForeName>Maryam</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guillot</LastName>
            <ForeName>Jacques</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Dynamic Research Group, UPEC, EnvA, USC Anses, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Dermatology Parasitology Mycology Department, Oniris Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation, Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taghipour</LastName>
            <ForeName>Simin</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Parasitology and Mycology, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rezaei-Matehkolaei</LastName>
            <ForeName>Ali</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-3119-8342</Identifier>
            <AffiliationInfo>
              <Affiliation>Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>RefSeq</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>MG572978</AccessionNumber>
              <AccessionNumber>MG573055</AccessionNumber>
              <AccessionNumber>MG573057</AccessionNumber>
              <AccessionNumber>MG573059</AccessionNumber>
              <AccessionNumber>MG561441</AccessionNumber>
              <AccessionNumber>MG561442</AccessionNumber>
              <AccessionNumber>MG561647</AccessionNumber>
              <AccessionNumber>MT573332</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Mycoses</MedlineTA>
        <NlmUniqueID>8805008</NlmUniqueID>
        <ISSNLinking>0933-7407</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>304NUG5GF4</RegistryNumber>
          <NameOfSubstance UI="D017964">Itraconazole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G7RIW8S0XP</RegistryNumber>
          <NameOfSubstance UI="D000077291">Terbinafine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J82SB7FXWB</RegistryNumber>
          <NameOfSubstance UI="C431707">efinaconazole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>RE91AN4S8G</RegistryNumber>
          <NameOfSubstance UI="C112528">luliconazole</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000935" MajorTopicYN="Y">Antifungal Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003883" MajorTopicYN="Y">Arthrodermataceae</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017964" MajorTopicYN="N">Itraconazole</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077291" MajorTopicYN="N">Terbinafine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">
Arthroderma
</Keyword>
        <Keyword MajorTopicYN="N">
Nannizzia
</Keyword>
        <Keyword MajorTopicYN="N">antifungal susceptibility</Keyword>
        <Keyword MajorTopicYN="N">efinaconazole</Keyword>
        <Keyword MajorTopicYN="N">luliconazole</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>17</Hour>
          <Minute>35</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34861084</ArticleId>
        <ArticleId IdType="doi">10.1111/myc.13408</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>de Hoog GS, Dukik K, Monod M, et al. Toward a novel multilocus phylogenetic taxonomy for the dermatophytes. Mycopathologia. 2017;182(1-2):5-31.</Citation>
        </Reference>
        <Reference>
          <Citation>Nardoni S, Mugnaini L, Papini R, Fiaschi M, Mancianti F. Canine and feline dermatophytosis due to Microsporum gypseum: a retrospective study of clinical data and therapy outcome with griseofulvin. J De Mycol Med. 2013;23(3):164-167.</Citation>
        </Reference>
        <Reference>
          <Citation>Dolenc-Voljč M, Gasparič J. Human infections with Microsporum gypseum complex (Nannizzia gypsea) in Slovenia. Mycopathologia. 2017;182(11):1069-1075.</Citation>
        </Reference>
        <Reference>
          <Citation>Taghipour S, Abastabar M, Piri F, et al. Diversity of geophilic dermatophytes species in the soils of Iran; the significant preponderance of Nannizzia fulva. J Fungi. 2021;7(5):345.</Citation>
        </Reference>
        <Reference>
          <Citation>Hayette M-P, Sacheli R. Unusual species of dermatophytes: rarely identified or new? Mycopathologia. 2017;182(1):203-213.</Citation>
        </Reference>
        <Reference>
          <Citation>Uhrlaß S, Mayser P, Schwarz R, et al. Dermatomycoses due to Nannizzia praecox (formerly Microsporum praecox) in Germany: case reports and review of the literature. Mycopathologia. 2018;183(2):391-398.</Citation>
        </Reference>
        <Reference>
          <Citation>Uhrlaß S, Mey S, Storch S, et al. Nannizzia incurvata as a rare cause of favus and tinea corporis in Cambodia and Vietnam. Indian J Dermatol Venereol Leprol. 2021;87(4).</Citation>
        </Reference>
        <Reference>
          <Citation>Mattei AS, Beber MA, Madrid IM. Dermatophytosis in small animals. SOJ Microbiol Infect Dis. 2014;2(3):1-6. https://pdfs.semanticscholar.org/0ae1/016b2f48d8386727d580a6d9fbc2910f33f1.pdf</Citation>
        </Reference>
        <Reference>
          <Citation>Gnat S, Łagowski D, Dyląg M, Nowakiewicz A. European Hedgehogs (Erinaceus europaeus L.) as a reservoir of dermatophytes in Poland. Microb Ecol. 2021;1-13.</Citation>
        </Reference>
        <Reference>
          <Citation>Saunte D, Pereiro-Ferreirós M, Rodríguez-Cerdeira C, et al. Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic. J Eur Acad Dermatol Venereol. 2021;35(7):1582-1586.</Citation>
        </Reference>
        <Reference>
          <Citation>Taghipour S, Shamsizadeh F, Pchelin IM, et al. Emergence of terbinafine resistant Trichophyton mentagrophytes in Iran, harboring mutations in the squalene epoxidase (SQLE) gene. Infec Drug Res. 2020;13:845.</Citation>
        </Reference>
        <Reference>
          <Citation>Wayne P Reference method for broth dilution antifungal susceptibility testing of flamentous fungi, 3rd ed. Approved standard CLSI document M38-A3 Clinical and Laboratory Standards Institute. 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Shamsizadeh F, Ansari S, Zarei Mahmoudabadi A, et al. In vitro antifungal susceptibility patterns of Trichophyton benhamiae complex isolates from diverse origin. Mycoses. 2021;64:1378.</Citation>
        </Reference>
        <Reference>
          <Citation>Rezaei-Matehkolaei A, Khodavaisy S, Alshahni MM, et al. In vitro antifungal activity of novel triazole efinaconazole and five comparators against dermatophyte isolates. Antimicrob Agents Chemother. 2018;62(5):e02423.</Citation>
        </Reference>
        <Reference>
          <Citation>Niwano Y, Kuzuhara N, Kodama H, Yoshida M, Miyazaki T, Yamaguchi H. In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemother. 1998;42(4):967-970.</Citation>
        </Reference>
        <Reference>
          <Citation>Fernández-Torres B, Carrillo A, Martın E, et al. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother. 2001;45(9):2524-2528.</Citation>
        </Reference>
        <Reference>
          <Citation>Perea S, Fothergill AW, Sutton DA, Rinaldi MG. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol. 2001;39(1):385-388.</Citation>
        </Reference>
        <Reference>
          <Citation>Hofbauer B, Leitner I, Ryder N. In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin. Med Mycol. 2002;40(2):179-183.</Citation>
        </Reference>
        <Reference>
          <Citation>Magagnin CM, Stopiglia CDO, Vieira FJ, et al. Antifungal susceptibility of dermatophytes isolated from patients with chronic renal failure. An Bras Dermatol. 2011;86:694-701.</Citation>
        </Reference>
        <Reference>
          <Citation>Sharifzadeh A, Shokri H, Khosravi AR. In vitro evaluation of antifungal susceptibility and keratinase, elastase, lipase and DN ase activities of different dermatophyte species isolated from clinical specimens in Iran. Mycoses. 2016;59(11):710-719.</Citation>
        </Reference>
        <Reference>
          <Citation>Lana AJD, Pippi B, Carvalho AR, et al. In Vitro additive effect on griseofulvin and terbinafine combinations against multidrug-resistant dermatophytes. Brazilian J Pharm Sci. 2018;54:2175. https://doi.org/10.1590/s2175-97902018000217149</Citation>
        </Reference>
        <Reference>
          <Citation>Curatolo R, Juricevic N, Leong C, Bosshard PP. Antifungal susceptibility testing of dermatophytes: Development and evaluation of an optimised broth microdilution method. Mycoses. 2021;64(3):282-291.</Citation>
        </Reference>
        <Reference>
          <Citation>Katiraee F, Kosari YK, Soltani M, Shokri H, Minooieanhaghighi MH. Molecular identification and antifungal susceptibility patterns of dermatophytes isolated from companion animals with clinical symptoms of dermatophytosis. Journal of Veterinary Research. 2021;65(2):175-182.</Citation>
        </Reference>
        <Reference>
          <Citation>Itoi S, Kano R, Hasegawa A, Kamata H. In vitro activities of antifungal agents against clinical isolates of dermatophytes from animals. J Vet Med Sci. 2012;12:3280801.</Citation>
        </Reference>
        <Reference>
          <Citation>Kano R, Oshimo K, Fukutomi T, Kamata H. Antifungal Susceptibility of Japanese Isolates of Nannizia fulva (Formerly Microsporum fulvum). Med Mycol J. 2019;60(1):23-25.</Citation>
        </Reference>
        <Reference>
          <Citation>Jo Siu WJ, Tatsumi Y, Senda H, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013;57(4):1610-1616.</Citation>
        </Reference>
        <Reference>
          <Citation>Indira G. In vitro antifungal susceptibility testing of 5 antifungal agents against dermatophytic species by CLSI (M38-A) micro dilution method. Clin Microbial. 2014;3(3):145.</Citation>
        </Reference>
        <Reference>
          <Citation>Bueno J, Martinez C, Zapata B, Sanclemente G, Gallego M, Mesa A. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Clin Exper Dermat Experi Dermatol. 2010;35(6):658-663.</Citation>
        </Reference>
        <Reference>
          <Citation>Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol. 2003;149(2):296-305.</Citation>
        </Reference>
        <Reference>
          <Citation>Adimi P, Hashemi SJ, Mahmoudi M, et al. In-vitro activity of 10 antifungal agents against 320 dermatophyte strains using microdilution method in Tehran. Iranian J Pharmac Res. 2013;12(3):537.</Citation>
        </Reference>
        <Reference>
          <Citation>Nenoff P, Krüger C, Paasch U, Ginter-Hanselmayer G. Mycology-an update Part 3: Dermatomycoses: topical and systemic therapy. J Der Deutschen Dermatol Gesellschaft. 2015;13(5):387-411. https://onlinelibrary.wiley.com/doi/full/10.1111/ddg.12689</Citation>
        </Reference>
        <Reference>
          <Citation>Krakhecke AG, Afonso E, Ferreira JC, Candido RC. In vitro susceptibility testing of Microsporum gypseum isolated from healthy cattle and soil samples against itraconazole, terbinafine, fluconazole and topical veterinarian drugs. Mycopathologia. 2005;159(3):377-380.</Citation>
        </Reference>
        <Reference>
          <Citation>Dias MFRG, Bernardes-Filho F, Quaresma-Santos MVP, Amorim AGdF, Schechtman RC, Azulay DR. Treatment of superficial mycoses: review-part II. An Bras Dermatol. 2013;88:937-944.</Citation>
        </Reference>
        <Reference>
          <Citation>Monod M, Feuermann M, Salamin K, et al. Trichophyton rubrum azole resistance mediated by a new ABC transporter, TruMDR3. Antimicrob Agents Chemother. 2019;63(11):e00863-e819.</Citation>
        </Reference>
        <Reference>
          <Citation>Piraccini BM, Iorizzo M, Lencastre A, Nenoff P, Rigopoulos D. Ciclopirox hydroxypropyl chitosan (HPCH) nail lacquer: a review of its use in onychomycosis. Dermatol Ther. 2020;1-13.</Citation>
        </Reference>
        <Reference>
          <Citation>Gupta AK, Mays RR, Versteeg SG, Shear NH, Friedlander SF. Onychomycosis in children: Safety and efficacy of antifungal agents. Pediatr Dermatol. 2018;35(5):552-559.</Citation>
        </Reference>
        <Reference>
          <Citation>Iwata A, Watanabe Y, Kumagai N, et al. In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal. Antimicrob Agents Chemother. 2014;58(8):4920-4922.</Citation>
        </Reference>
        <Reference>
          <Citation>Markham A. Tavaborole: first global approval. Drugs. 2014;74(13):1555-1558.</Citation>
        </Reference>
        <Reference>
          <Citation>Abastabar M, Haghani I, Shokohi T, et al. Low in vitro antifungal activity of tavaborole against yeasts and molds from onychomycosis. Antimicrob Agents Chemother. 2018;62(12):e01632.</Citation>
        </Reference>
        <Reference>
          <Citation>Mazzantini D, Celandroni F, Calvigioni M, Lupetti A, Ghelardi E. In vitro resistance and evolution of resistance to tavaborole in Trichophyton rubrum. Antimicrob Agents Chemother. 2021;65(4):e02324.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
